Navigation Links
Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
Date:11/6/2012

SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinsons Disease
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
4. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
6. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
7. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
8. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
9. IntelliCell BioSciences Files Patent Application for a New Mechanical Method to Separate Stromal Vascular Fraction from the Blood Vessels in Adipose Tissue
10. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis Pharmaceuticals, ... it has earned a $4 million milestone payment ... associated with the initiation of a Phase 3 ... resistant (MDR), gram-negative bacterial infections.  The Phase 3 ... evaluate the efficacy and safety of plazomicin compared ...
(Date:9/17/2014)... ALTO, Calif. , Sept. 17, 2014  Neuraltus ... the Company,s Phase 2 clinical program of NP001 for ... Lou Gehrig,s disease) are being highlighted today in ... the ALS Research Group , being held in ... to a  post hoc  analysis, administration of a high ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 2014 Kristen Yarker, MSc, RD recently announced ... children 9 months to 2 years old who are seeking ... picky eaters from developing by encouraging healthy eating habits from ... to 2 years): How to Transition From Baby Food to ... the Nutrition They Need)” is a new online seminar based ...
(Date:9/17/2014)... Wailea, Maui, HI (PRWEB) September 17, 2014 ... has announced the eighth annual Wailea Tennis Fantasy ... 19-23, 2014 at Maui’s prestigious Wailea Tennis Club, with ... ranked Lindsay Davenport returning to Wailea, Maui for her ... world-class instruction and match play with Davenport, recently inducted ...
(Date:9/17/2014)... In a new video released for ... expert on the condition known as PPP, demonstrates a proven ... or PPP, is a condition that affects mostly uncircumcised men ... affected as well. The condition is characterized by small bumps ... is not a sexually transmitted disease and generally has no ...
(Date:9/17/2014)... 17, 2014 Request A Test , ... is offering 10% off drug testing through the ... drug tests, including those ordered by employers for workplace or ... of this discount by using promo code DRUG10 when placing ... positives on workplace drug testing, especially for marijuana or THC. ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... from University of Missouri, Columbia indicates that the masculine tendencies ... been assumed all along that such tendencies were the barriers ... this issue. ,Generally it has been said that ... quality is said to aid in their recovery in traumatic ...
... major Ranbaxy Laboratories Ltd says it has obtained tentative approval ... market a drug for insomnia. ,The US unit ... Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem ... therapeutic effect as that of Ambien tablets of Sanofi Aventis ...
... Health Services called Frontpoint Systems (http://www.frontpointsystems.co.uk /weblog) has ... Royal College of Obstetricians & Gynaecologists indicating a ... ,The site highlights what is wrong ... in the UK has published a letter from ...
... of Virginia Health System suggests that composition of plaque deposits ... a stroke. ,Published in the March edition of ... deposits in the carotid arteries of 102 patients treated at ... likely to have a stroke, physicians may want to take ...
... the risk of death among children aged 12 to 48 ... conducted by researchers at the Johns Hopkins Bloomberg School of ... in mortality among children 1 to11 months of age. The ... The Lancet. ,Zinc is one of the ...
Cached Medicine News:Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3Health News:More Evidence of Racial Discrimination in the NHS 2Health News:Calcium in Arterial Plaque is a Good Indicator for Risk of Stroke 2Health News:Zinc Supplements Enhance Immunity in Children 2
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: